These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1748064)

  • 1. One-year treatment with the aldose reductase inhibitor, ponalrestat, in diabetic neuropathy.
    Ziegler D; Mayer P; Rathmann W; Gries FA
    Diabetes Res Clin Pract; 1991 Oct; 14(1):63-73. PubMed ID: 1748064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months. United Kingdom/Scandinavian Ponalrestat Trial.
    Sundkvist G; Armstrong FM; Bradbury JE; Chaplin C; Ellis SH; Owens DR; Rosén I; Sönksen P
    J Diabetes Complications; 1992; 6(2):123-30. PubMed ID: 1611136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy.
    Valensi P; Attali JR; Gagant S
    Diabet Med; 1993 Dec; 10(10):933-9. PubMed ID: 8306589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 12-month randomized controlled study of the aldose reductase inhibitor ponalrestat in patients with chronic symptomatic diabetic neuropathy.
    Krentz AJ; Honigsberger L; Ellis SH; Hardman M; Nattrass M
    Diabet Med; 1992 Jun; 9(5):463-8. PubMed ID: 1611835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ponalrestat, an aldose reductase inhibitor, on neutrophil killing of Escherichia coli and autonomic function in patients with diabetes mellitus.
    Boland OM; Blackwell CC; Clarke BF; Ewing DJ
    Diabetes; 1993 Feb; 42(2):336-40. PubMed ID: 8425670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy.
    Gill JS; Williams G; Ghatei MA; Hetreed AH; Mather HM; Bloom SR
    Diabete Metab; 1990; 16(4):296-302. PubMed ID: 2125013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and neurophysiological studies of aldose reductase inhibitor ponalrestat in chronic symptomatic diabetic peripheral neuropathy.
    Florkowski CM; Rowe BR; Nightingale S; Harvey TC; Barnett AH
    Diabetes; 1991 Jan; 40(1):129-33. PubMed ID: 1901808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy.
    Nakayama M; Nakamura J; Hamada Y; Chaya S; Mizubayashi R; Yasuda Y; Kamiya H; Koh N; Hotta N
    Diabetes Care; 2001 Jun; 24(6):1093-8. PubMed ID: 11375376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of diabetic autonomic neuropathy with an aldose reductase inhibitor.
    Faes TJ; Yff GA; DeWeerdt O; Lanting P; Heimans JJ; Bertelsmann FW
    J Neurol; 1993; 240(3):156-60. PubMed ID: 8482988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of aldose reductase inhibition on resistance to ischemic conduction block in diabetic subjects.
    Price DE; Alani SM; Wales JK
    Diabetes Care; 1991 May; 14(5):411-3. PubMed ID: 1905621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.
    Sima AA; Prashar A; Zhang WX; Chakrabarti S; Greene DA
    J Clin Invest; 1990 May; 85(5):1410-20. PubMed ID: 2110189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats.
    Cameron NE; Cotter MA; Robertson S
    Q J Exp Physiol; 1989 Nov; 74(6):917-26. PubMed ID: 2512591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.
    Bril V; Buchanan RA
    Diabetes Care; 2006 Jan; 29(1):68-72. PubMed ID: 16373898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats.
    Yagihashi S; Kamijo M; Ido Y; Mirrlees DJ
    Diabetes; 1990 Jun; 39(6):690-6. PubMed ID: 2140802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
    Santiago JV; Snksen PH; Boulton AJ; Macleod A; Beg M; Bochenek W; Graepel GJ; Gonen B
    J Diabetes Complications; 1993; 7(3):170-8. PubMed ID: 8343611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural progression of diabetic peripheral neuropathy in the Zenarestat study population.
    Brown MJ; Bird SJ; Watling S; Kaleta H; Hayes L; Eckert S; Foyt HL;
    Diabetes Care; 2004 May; 27(5):1153-9. PubMed ID: 15111537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac abnormalities in diabetic patients with neuropathy: effects of aldose reductase inhibitor administration.
    Johnson BF; Nesto RW; Pfeifer MA; Slater WR; Vinik AI; Chyun DA; Law G; Wackers FJ; Young LH
    Diabetes Care; 2004 Feb; 27(2):448-54. PubMed ID: 14747227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year's treatment with sorbinil.
    O'Hare JP; Morgan MH; Alden P; Chissel S; O'Brien IA; Corrall RJ
    Diabet Med; 1988 Sep; 5(6):537-42. PubMed ID: 2974776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
    Sima AA; Greene DA; Brown MB; Hohman TC; Hicks D; Graepel GJ; Bochenek WJ; Beg M; Gonen B
    J Diabetes Complications; 1993; 7(3):157-69. PubMed ID: 8343610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
    Nicolucci A; Carinci F; Cavaliere D; Scorpiglione N; Belfiglio M; Labbrozzi D; Mari E; Benedetti MM; Tognoni G; Liberati A
    Diabet Med; 1996 Dec; 13(12):1017-26. PubMed ID: 8973882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.